NASDAQ · NAUT
Healthcare · Biotechnology
$1.87
Down-$0.05 (-2.67%)
Updated Oct 6, 2026, 5:54 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NAUT
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
NAUT closed at $1.87 after 20 trading sessions, up 101.53% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $2.185 | $2.475 | $1.81 | $1.87 | 29.56M |
| Oct 2, 2026 | $1.65 | $1.97 | $1.598 | $1.96 | 14.19M |
| Oct 1, 2026 | $1.43 | $1.6761 | $1.38 | $1.57 | 8.51M |
| Sep 30, 2026 | $1.46 | $1.49 | $1.29 | $1.42 | 12.79M |
| Sep 29, 2026 | $1.19 | $1.595 | $1.08 | $1.365 | 22.39M |
| Sep 28, 2026 | $1.00 | $1.17 | $0.9903 | $1.11 | 4.1M |
| Sep 25, 2026 | $1.00 | $1.04 | $0.9617 | $0.9627 | 681.68K |
| Sep 24, 2026 | $0.94 | $1.01 | $0.94 | $0.9905 | 518.81K |
| Sep 23, 2026 | $1.00 | $1.02 | $0.95 | $0.9539 | 386.71K |
| Sep 22, 2026 | $0.96 | $1.0199 | $0.95 | $0.9994 | 606.82K |
| Sep 21, 2026 | $0.965 | $0.965 | $0.90 | $0.9547 | 738K |
| Sep 18, 2026 | $0.9661 | $0.9978 | $0.9384 | $0.966 | 1.78M |
| Sep 17, 2026 | $1.01 | $1.03 | $0.96 | $0.9717 | 679.31K |
| Sep 16, 2026 | $0.9179 | $1.00 | $0.91 | $0.9721 | 1.15M |
| Sep 15, 2026 | $0.9005 | $0.9679 | $0.8802 | $0.8911 | 945.05K |
| Sep 14, 2026 | $1.01 | $1.02 | $0.9009 | $0.9063 | 1.23M |
| Sep 11, 2026 | $1.00 | $1.04 | $0.994 | $1.02 | 826.87K |
| Sep 10, 2026 | $1.12 | $1.1273 | $0.9727 | $0.9896 | 1.97M |
| Sep 9, 2026 | $0.9442 | $1.14 | $0.9317 | $1.12 | 3.89M |
| Sep 8, 2026 | $0.9071 | $0.9957 | $0.89 | $0.9279 | 1.07M |
The latest Smart Investors Daily articles mentioning NAUT.
Company
Market Activity
Research & News
NAUT research
Company profile and research snapshot.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Roth Capital | Buy | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Feb 27, 2026 | Guggenheim | Buy | — |
| Dec 5, 2024 | Goldman Sachs | Sell | — |
| Jun 27, 2024 | Guggenheim | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 29, 2026
Analysts initiate coverage: Buy on Nautilus ($3.50) and SpaceX ($200); Outperform on FuelCell ($24) and Butterfly ($15); Market Perform on O’Reilly ($94).
Benzinga · Sep 29, 2026
Roth Capital analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $3.5.
Benzinga · Sep 11, 2026
-SEC Filing
Benzinga · Sep 9, 2026
Leerink Partners analyst Puneet Souda initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Outperform rating and announces Price Target of $4.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NAUT.
